Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 11, 2000, Pages 3112-3117

  Heaton, V J ^a   Ambler, J E ^a   Fisher, L M ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GEMIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CROSS RESISTANCE; DNA CLEAVAGE; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; CIPROFLOXACIN; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NAPHTHYRIDINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0033744515     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.11.3112-3117.2000     Document Type: Article

References (36)

1. The role of topoisomerase IV in partitioning DNA replicons and the structure of catenated intermediates in DNA replication
2. Engineering the specificity of antibacterial fluoroquinolones: Benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase
3. Community-acquired pneumonia
4. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
5. Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone
6. Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones
7. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY antimicrobial surveillance program
8. DNA gyrase, topoisomerase IV, and the 4-quinolones
9. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - Findings of the Alexander Project 1992-1996
10. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target for quinolones
11. Primary targets of fluoroquinolones in Streptococcus pneumoniae
12. Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
13. DNA gyrase: An enzyme that introduces superhelical turns into DNA
14. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
15. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
16. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms
17. Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition
18. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
19. New topoisomerase essential for chromosomal segregation in E. coli
20. DNA gyrase action involves the introduction of transient double strand breaks into DNA
21. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins
22. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of quinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
23. Mechanisms of quinolone resistance
24. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone
25. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
26. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in fluoroquinolone resistance
27. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
28. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
29. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: Overexpression, purification, and differential inhibition by fluoroquinolones
30. Characterization of a mutation in the pare gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
31. New quinolones and gram-positive bacteria
32. DNA sequencing with chain-terminating inhibitors
33. Contribution of mutations in the gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro
34. DNA topoisomerases
35. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone
36. Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli